HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galderma Pioneers NDA Path Into OTC Acne Treatment Market

This article was originally published in The Rose Sheet

Executive Summary

FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical acne treatment for consumers 12 years old and up.

You may also be interested in...



Private-Equity Investors Poised To Acquire Nestlé Skin Health, Promising US Expansion

After working hard to turnaround its troubled Skin Health dermatology operation, Nestlé looks set to offload the business to a consortium of private-equity buyers. The consortium - led by EQT - have identified expansion in the US consumer health market as an immediate priority.

Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop

While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.

Galderma's Acne Drug Switch Gets Unanimous NDAC Support

If approved by FDA, the product, to be marketed as Differin Gel, would be the first OTC drug available in the US that contains an ingredient in the retinoid class – adapalene 0.1 gel. Discussion at the April 15 meeting of FDA's Nonprescription Drugs Advisory Committee focused largely on the issue of self-selection among pregnant women.

Topics

Related Companies

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel